<DOC>
	<DOCNO>NCT02792803</DOCNO>
	<brief_summary>The purpose study provide evidence efficacy Xalatan superior Apo-latanoprost Co-latanoprost reduction intraocular pressure patient primary open angle glaucoma . The study also aim prove tolerability Xalatan term ocular hyperemia equivalent generic counterpart .</brief_summary>
	<brief_title>A Comparison Xalatan ( Latanoprost ) Apo-latanoprost Co-latanoprost Treatment Glaucoma</brief_title>
	<detailed_description>Since introduction Xalatan generic version latanoprost enter Canadian marketplace Apo-latanoprost ( Apotex Inc. ) , Co-latanoprost ( Cobalt Pharmaceuticals Co. ) Sandoz latanoprost ( Sandoz Canada Inc. ) . The exact formulation different preparation latanoprost may differ manufacturer , although active ingredient suppose vary within 15 % tolerance . In topical ocular medication multi-dose dispenser , stability drug ability penetrate cornea eye may affect efficacy drug . There clinical trial compare efficacy generic version latanoprost Xalatan , clinical trial compare efficacy different generic version . Empirical evidence base clinical experience suggest least generic version latanoprost may effective brand version ( Xalatan ) . Intraocular pressure often observed increase switch brand generic version latanoprost , opposite rarely ever observe . The purpose study compare efficacy Xalatan two popular generic version latanoprost available Canada ( Apo-latanoprost Co-latanoprost ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Patients â‰¥ 18 year old , diagnose primary open angle glaucoma ocular hypertension IOP currently control prostaglandin analogue monotherapy ( latanoprost , bimatoprost travoprost ) , judge investigator Best correct visual acuity bad 0.6 logMAR 20/80 Snellen either eye . Patients mean IOP either eye screening exam visit great 36 mmHg History ocular trauma within past six ( 6 ) month . History ocular infection ocular inflammation within past three ( 3 ) month . History chronic recurrent severe inflammatory eye disease ( i.e. , scleritis , uveitis ) History severe serious hypersensitivity component study medication . Any abnormality prevent reliable applanation tonometry either eye . Intraocular surgery within past six ( 6 ) month determine patient history and/or examination . Patients cup/disc ratio great 0.80 either eye . Patients severe central visual field loss either eye define sensitivity less equal 10 dB least two ( 2 ) four ( 4 ) visual field test point closest point fixation . Visual field test must within 6 month eligibility assessment . History clinically significant progressive retinal disease retinal degeneration , diabetic retinopathy retinal detachment . Current use ANY glucocorticoid administer route . Patient must wash glucocorticoid least 4 week prior study entry . Use systemic prostaglandin prostaglandin analogue within last three month . Current use topical nonsteroidal antiinflammatory agent inhibit cyclooxygenase prostaglandin analogue synthesis . Any form glaucoma openangle glaucoma ( without pigment dispersion pseudoexfoliation component ) . Current use topical nonsteroidal anti inflammatory agent inhibit cyclooxygenase prostaglandin analogue synthesis . Angle grade less 2 ( extreme narrow angle complete partial closure ) measure gonioscopy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>POAG</keyword>
	<keyword>Primary open angle glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Xalatan</keyword>
	<keyword>Latanoprost</keyword>
	<keyword>Ocular Hyperemia</keyword>
	<keyword>IOP</keyword>
	<keyword>Intraocular Pressure</keyword>
	<keyword>Allergan</keyword>
	<keyword>prostaglandin</keyword>
</DOC>